| Literature DB >> 34646370 |
Yining Shao1, Guilin Yang1, Jiaying Lin2, Xiaofeng Fan1, Yue Guo1, Wentao Zhu1, Ying Cai1, Huiyu Huang1, Die Hu1, Wei Pang1, Yanjun Liu3, Yiwen Li2, Jiaji Cheng2, Xiaoqian Xu1.
Abstract
The rapid development of chiral inorganic nanostructures has greatly expanded from intrinsically chiral nanoparticles to more sophisticated assemblies made by organics, metals, semiconductors, and their hybrids. Among them, lots of studies concerning on hybrid complex of chiral molecules with achiral nanoparticles (NPs) and superstructures with chiral configurations were accordingly conducted due to the great advances such as highly enhanced biocompatibility with low cytotoxicity and enhanced penetration and retention capability, programmable surface functionality with engineerable building blocks, and more importantly tunable chirality in a controlled manner, leading to revolutionary designs of new biomaterials for synergistic cancer therapy, control of enantiomeric enzymatic reactions, integration of metabolism and pathology via bio-to nano or structural chirality. Herein, in this review our objective is to emphasize current research state and clinical applications of chiral nanomaterials in biological systems with special attentions to chiral metal- or semiconductor-based nanostructures in terms of the basic synthesis, related circular dichroism effects at optical frequencies, mechanisms of induced optical chirality and their performances in biomedical applications such as phototherapy, bio-imaging, neurodegenerative diseases, gene editing, cellular activity and sensing of biomarkers so as to provide insights into this fascinating field for peer researchers. © The author(s).Entities:
Keywords: chiral inorganic nanomaterials; gene editing; induced optical chirality; neurodegenerative diseases; phototherapy
Mesh:
Substances:
Year: 2021 PMID: 34646370 PMCID: PMC8490512 DOI: 10.7150/thno.64511
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Inorganic nanostructures with chirality. A. Intrinsically chiral nanostructure or lattice. B. Achiral nanoparticle capped with chiral molecules on the surface. C. Nanostructures with chiral shape. D. Chiral arrangement of achiral nanoparticles. Adapted with permission from 14, copyright 2020 Wiley-VCH.
Figure 2The chiral induction method of nanomaterials. (A-D). Chiral cores A. Au38(SCH2CH2Ph)24; B. Pen-HgS; C. Eu3+-TbPO4∙H2O; D. CdSe/ZnS QDs; (E-J). Ligand-induced chirality; E. N-Isobutyryl-Cys-Au; F. 5'-GMP GNFs; G. Pro/Asp-WO3-x·H2O; H. Cys-CdSe; I. Cys-WZ/ZB CdSe NPLs; J. Cys-MoO3-x; (K-P). Self-assembly of nanomaterials; K. DNA-Au; L. Au1/L-L; M. Au2+Au3+Ag+ QD; N. NiMoO4·xH2O; O. Gd2O3 Nanohelices; P. CdTe NPs. Q. chiral Ag NHs Panel A is adapted with permission from 24, copyright 2015 Springer Nature. Panel B is adapted with permission from 25, copyright 2020 American Chemical Society. Panel C is adapted with permission from 26, copyright 2019 Wiley-VCH. Panel D is adapted with permission from 27, copyright 2015 American Chemical Society. Panel E is adapted with permission from 29, copyright 2006 American Chemical Society. Panel F is adapted with permission from 30, copyright 2012 Springer Nature. Panel G is adapted with permission from 31, copyright 2017 American Chemical Society. Panel H is adapted with permission from 32, copyright 2013 American Chemical Society. Panel I is adapted with permission from 33, copyright 2018 American Chemical Society. Panel J is adapted with permission from 7, copyright 2018 Wiley-VCH. Panel K is adapted with permission from 34, copyright 2012 Springer Nature. Panel L is adapted with permission from 38, copyright 2019 Wiley-VCH. Panel M is adapted with permission from 41, copyright 2012 American Chemical Society. Panel N is adapted with permission from 44, copyright 2019 Wiley-VCH. Panel O is adapted with permission from 48, copyright 2020 American Chemical Society. Panel P is adapted with permission from 4, copyright 2015 Springer Nature. Panel Q is adapted with permission from 50, copyright 2020 Springer Nature.
Figure 3Schematic illustration of biological and clinical application aspects of chiral inorganic nanomaterials.
Figure 4Schematic representation of synergistic diagnosis and treatment of tumor by chiral inorganic nanomaterials. A. Mechanism of PTT diagram; B. Mechanism of PDT diagram; C. Mechanism of photoacoustic imaging (PAI) diagram; D. Synergistic diagnosis and treatment of tumor diagram.
Figure 5The application of chiral nanomaterials in phototherapy of tumor. (A-E) The application in PTT: A. GNFs; B. optically active Cu2-xS nanocrystals (Cys-Cu2-xS); C. chiral β-HgS QDs; D. chiral sub-stoichiometric molybdenum oxide nanomaterials (L-/D-Cys-MoO3-x); (E-F) The application in PDT: E. chiral CdSe/CdS dot/rod NCs; F. DNA-Au; (G-H) the application in PAI and synergistic diagnosis: G. chiral shell-satellites (SSs) gold nanostructures; H. chiral alloy AuCuAu HNRs. Panel A is adapted with permission from 30, copyright 2012 Springer Nature. Panel B is adapted with permission from 78, copyright 2020 the Royal Society of Chemistry. Panel C is adapted with permission from 79, copyright 2019 Elsevier. Panel D is adapted with permission from 6, copyright 2019 Wiley-VCH and 80, copyright 2021 Elsevier. Panel E is adapted with permission from 85, copyright 2019 the Royal Society of Chemistry. Panel F is adapted with permission from 86, copyright 2017 Springer Nature. Panel G is adapted with permission from 89, copyright 2017 Wiley-VCH. Panel H is adapted with permission from 90, copyright 2020 Wiley-VCH.
Figure 6The application of chiral nanomaterials in neurodegenerative disease treatment. A. CuxO nanoparticle clusters; B. GSH-Au NPs; C. Pen-FexCuySe; D. C30(D)S5-C20(L). Panel A is adapted with permission from 96 copyright 2019 American Chemical Society. Panel B is adapted with permission from 97, copyright 2020 Springer Nature. Panel C is adapted with permission from 98, copyright 2020 Wiley-VCH. Panel D is adapted with permission from 9, copyright 2020 Springer Nature.
Figure 7The application of chiral nanomaterials in gene editing. A. Cys-CdTe; B. Cys-carbon dots. Panel A is adapted with permission from 10, copyright 2018 Springer Nature. Panel B is adapted with permission from 101, copyright 2020 Wiley-VCH.
Figure 8The application of chiral nanomaterials in regulating cellular activity. A. GSH-UYTe; B. Cys-Cu2-xS nanoclusters; C. GSH-CdTe QDs; D. aB2MG-TPP@CSNRs; E. Pen-CuxCoyS NPs; F. GSH@Se NPs; G. L(D)-PAV-Au NPs; H. Pen-Au films. Panel A is adapted with permission from 106, copyright 2018 Springer Nature. Panel B is adapted with permission from 78, copyright 2020 the Royal Society of Chemistry. Panel C is adapted with permission from 107, copyright 2011 Wiley-VCH. Panel D is adapted with permission from 108, copyright 2020 Wiley-VCH. Panel E is adapted with permission from 109, copyright 2020 Wiley-VCH. Panel F is adapted with permission from 110, copyright 2020 Wiley-VCH. Panel G is adapted with permission from 111, copyright 2016 Springer Nature. Panel H is adapted with permission from 112, copyright 2017 Springer Nature.
Figure 9The application of chiral nanomaterials in biosensing. A. L(D)-NIBC and L(D)-Cys-β-HgS QDs; B. L-Cysteine-functionalized CdSe/CdS dot/rod NCs; C. DPA/Cys-CdS QDs; D. D-/L-Pen-Cu2-xS QDs; E. Chirality Au@Ag NR dimers building by aptamer; F. Aptamers-driven chiral Ag@Au core-shell NP assemblies; G. GO-gold nanoparticle (GO-Au NP) assemblies; H. Y-DNA-driven construction of Au NP chiral C30S5S10 NSs; I. L-Tartaric acid-capped gold nanoparticles (L-TA-capped Au NPs). Panel A is adapted with permission from 79, copyright 2018 Elsevier. Panel B is adapted with permission from 85, copyright 2019 the Royal Society of Chemistry. Panel C is adapted with permission from 115, copyright 2018 Elsevier. Panel D is adapted with permission from 116, copyright 2019 Wiley-VCH. Panel E is adapted with permission from 137, copyright 2015 American Chemical Society. Panel F is adapted with permission from 138, copyright 2016 Wiley-VCH. Panel G is adapted with permission from 139, copyright 2017 Wiley-VCH. Panel H is adapted with permission from 140, copyright 2020 Wiley-VCH. Panel I is adapted with permission from 141, copyright 2017 the Royal Society of Chemistry.
Summary of biochemical and pharmaceutical detections based on chiral semiconductor-NPs
| Chiral nanostructures | Type of chirality | Analyte | Working concentration/Limit of detection (LOD) | Applications | Ref | |
|---|---|---|---|---|---|---|
|
| ||||||
| L-/D-Cys-CdS QDs | LIC | Ni2+ | 10-60 µМ/7.33 µМ | Detection |
| |
| Co2+ | 4-80 µМ/1.13 µМ | |||||
| L-Morphine D-Methamphetamine | -/- |
| ||||
| CdTe QDs | LIC | D-Cys | Enantiomeric excess of D-Cys: -100%-100%/- | Recognition |
| |
| N-Acetyl-L-Cysteine (NALC)-CdSe/CdS QDs | LIC | Tyr enantiomers | 4.0×10-5-1.2×10-3 M/- | Recognition |
| |
| Au NRs and CdTe@CdS QDs core-satellite structure | CAM | Cys enantiomers | -/10% | Recognition and quantification |
| |
| L-Pen-Cys-CdS QDs | LIC | Cd2+ | 65-200 µM/59.7 µM | Detection |
| |
| S2- | 7-125 µM/1.6 µM | |||||
| [Cys-CdS QDs]-Fe3+ | LIC | Pyrophosphate | 0.5-10 µM/0.11 µM | Detection |
| |
| DPA/Cys-CdS QDs | LIC | Cu2+ | 0.50-2.25 µM/0.34 µM | Detection |
| |
| Glucose | 50-250 µM/31 µM |
| ||||
| NALC-CdTe QDs | LIC | Phenylglycinol (PG) enantiomers | 10-7-10-5 M/10-7 M | Recognition |
| |
| L-/D-Cys-CdSe QDs | LIC | Pb2+ | -/4.9 nM | Detection |
| |
| L-/D-Cys-CdTe NPs | LIC | Recognize the specific sequence: GAT′ ATC | -/- | Recognition (and then cleave the DNA) (Site-selective photoinduced DNA cleavage and profiling) |
| |
| β- Cyclodextrin-CdSe/ZnS QDs | LIC | Pen enantiomers | L-Pen 0.8-5.0 mg/L/0.2 mg/L | D-Pen 0.1-5.0 mg/L/0.06 mg/L | Recognition |
|
| β-Cyclodextrin-functionalized CdSe/ZnS QDs with receptor-bound Rhodamine B | LIC | Aromatic amino acids enantiomers (Phe and Tyr) | -/1.0×10-6 M (4-hydroxytoluene,1-adamantanecarboxylic acid and 4-nitrophenol) | Detection |
| |
| α/β-Cyclodextrin-CdSe/ZnS QDs | LIC | Met enantiomers | 5×10-8-5×10-5 M/- | Recognition |
| |
| Methyl ester NALC capped-CdSe/ZnS QDs | LIC | R/S-Ketoprofen | -/- | Detection |
| |
| L-/D-Cys-CdSe/ZnS QDs | LIC | Carnitine enantiomers | 0.05-0.3 mM/ | Recognition and quantification |
| |
| ZnTPyP-CdTe QDs | CAM | D-Pro | 1.0×10-9-1.5×10-7 M/4.46×10-10 M | Detection |
| |
| D-Lys | 1.0×10-9-1.5×10-8 M/7.13×10-11 M | |||||
| L-Ser | 1.0×10-9-5.0×10-9 M/3.35×10-11 M | |||||
|
| ||||||
| β-Cyclodextrin-Mn-ZnS QDs | LIC | L-/D-Trp | 5.4 nM-6.0 µM/5.4 nM | Detection |
| |
| ZnO@Cys NPs | LIC | Dopamine (DA) content | 26.3-68.5 μM/0.791 μM | Detection |
| |
|
| ||||||
| L-/D-Pen-FexCuySe NPs | LIC | Recognition pentapeptide on Aβ42 fibrils | -/- | Recognition |
| |
|
| ||||||
| Magnetic nanoparticles (MNPs)-MoS2 QDs | LIC | Dual-mode detection | PL detection | CD detection | Detection |
|
| Avian influenza A: H4N6 | 128-0.0012 HAU/50 µL/0.00403 HAU/50 µL | 128-0.0128 HAU/50 µL/0.0381 HAU/50 µL | ||||
| H5N1 | 10 pg/mL-10 µg/mL/7.35 pg/mL | 100 pg/mL-10 µg/mL/80.92 pg/mL | ||||
| Cys-MoO2/GOx | LIC | D-Glucose | 200-1000 μM/0.446 μM | Recognition |
| |
| MoO2 NPs | LIC | Hg2+ | 0.1-4 nM/0.08 nM (D-Cys-MnO2 NPs) | 0.1-4 nM/0.12 nM (L-Cys-MnO2 NPs) | Detection |
|
*CAM represents for Chiral-Assemblies and Morphologies, while LIC represents for Ligand Induced Chirality.
Summary of biochemical and pharmaceutical detections based on chiral noble-NPs
| Chiral nanostructures | Type of chirality | Analyte | Working concentration/LOD | Applications | Reference | |
|---|---|---|---|---|---|---|
|
| ||||||
| Au NRs | CAM | Carnitine enantiomers | Enantiometric excess of L-Carnitine: -100%-100% | Recognition |
| |
| Gln enantiomers | D-Gln: -100%-100% | Recognition |
| |||
| DNA | -/3.7 aM | Detection |
| |||
| L-/D-Cys | L-Cys: -/1.40 µM | Detection |
| |||
| L-/D-GSH | L-GSH: -/1.93 µM | |||||
| L-Cys-Au NRs | LIC | Cu2 + | 20 pM-5 nM/7 pM | Detection |
| |
| Au nanosphere clusters | LIC | L-/D-Cys | 9×10-6 M/9×10-7 M | Detection |
| |
| Pen-Au NPs | LIC | 3,4-dihy-droxyphenylalanine (DOPA) enantiomers | -/- | Recognition |
| |
| Au NRs | CAM | Cys enantiomers | L-Cys: 0.625-2.50 µM/0.325 µM | Detection |
| |
| Au NP oligomers | CAM | Antibiotics | 0.05-5 ng/mL/0.014 ng/mL | Detection |
| |
| Au NP dimers | CAM | Bisphenol A (BPA) | 0.02-5 ng/mL/0.008 ng/mL | Detection |
| |
| Ag+ | 0.005-10 nM/2 pM | Detection |
| |||
| DNA methyltransferase | M.SssI MTase: 0.5-150 U/mL/0.27 U/mL | Detection |
| |||
| 8-hydroxy-2′-deoxyguanosine (8-OHdG) | 0.05-2 nM/33 pM | Detection |
| |||
| Intracellular ATP | 1.5-4.2 mM/0.2 mM | Detection |
| |||
| Intracellular telomerase | 0.8×10-12-32×10-12 IU/1.7×10-15 IU | Detection |
| |||
| L-Cys | 0.05-5 nM/20 pM | Recognition and quantification |
| |||
| Alpha-fetoprotein (AFP) | 0.02-5 ng/mL/11 pg/mL | Detection |
| |||
| Anti-BPA antibody and coating antigen coated Au20 and Au10 dimers | CAM | BPA | 0.05-10 ng/mL/0.02 ng/mL | Detection |
| |
| Au NR-UCNP tetramers | CAM | DNA | 3.3×10-8-3.3×10-5 nM/13.2 aM | Detection |
| |
| Au shell core-Au NP satellite | CAM | Ochratoxin A (OTA) | 0.1-5 pg/mL/0.037 pg/mL | Detection |
| |
| Core-satellite Au NP networks | CAM | L-/D-Carnitine | -/At pM level | Recognition |
| |
| L-/D-Cys modified Au electrode | LIC | L-/D-Carnitine | 10-6-10-2 M/- | Recognition |
| |
| Au films | CAM | Probe the second structure of Concanavalin A with a high β-sheet content | -/- | Recognition |
| |
| Au NP chiral pyramids | CAM | DNA | 10-5000 aM/3.4 aM | Detection |
| |
| Au NP dimer with metal deposition | CAM | DNA | 160 zM-1.6 pM/17 zM | Detection |
| |
| Au NR side by side structure | CAM | Hg2+ | 0.05-10 ng/mL/0.03 ng/mL | Detection |
| |
| Au-UCNP pyramids | CAM | Intracellular miRNA | 0.073-43.65 fmol/10 μg (RNA)/0.03 fmol/10 μg (RNA) | Detection and quantification |
| |
| Au NRs | CAM | Amyloid fibrils | -/- | Detection |
| |
| Two-layer core-satellite Au nanostructures (C30S5S10 NS) | CAM | Intracellular miRNA (Dual-signal method) | CD detection 0.011-20.94 amol/ng (RNA)/0.0051 amol/ng (RNA) | Raman signal 0.052-34.98 amol/ng (RNA)/2.81×10-2 amol/ng (RNA) | Detection and quantification |
|
| L-/D-GSH-Au NPs (3.3 nm) | LIC | Aβ peptides | -/- | Recognition |
| |
| Au NPs | CAM | -/23.4 ng/mL | Detection |
| ||
| GO-Au NP structures | CAM | MiR-21 | 0.07-13.68 amol/ng (RNA)/0.03 amol/ng (RNA) | Detection |
| |
| EpCAM | 8.47-74.78 pg/mL/3.63 pg/mL | |||||
| L-tartaric acid-capped Au NPs | LIC | L-/D-Mandelic acid (MA) | Enantiometric excess of L-MA: -100%-100% | Recognition |
| |
| Au@AgAu yolk-shell NRs-Au NPs core-satellite structure | CAM | Zn2+ | -/38.7 × 10-6 M (per 106 cells) | Detection |
| |
| Au@Ag-NR dimers | CAM | PSA | 0.1-50 aM/0.076 aM | Detection |
| |
| Chiral Ag NP-Au NP dimers | CAM | Environmental pollutants | Microcystin-LR (MCLR): 0.002-0.5 ng/mL/8×10-13 M | Detection |
| |
| PSA | 1×10-9-1×10-6 ng/mL/1.5 ×10-20 M | |||||
| Ag@Au core-shell NP (CSNP) assemblies | CAM | Circulating tumor cells with HER2 overexpression | In SK-BR-3 cells: 50-105 cells/mL/10±6 cells/mL | Separation |
| |
| Au@Ag core-shell NPs | CAM | OTA | 1-50 pg/mL/0.16 pg/mL | Detection |
| |
| Chiral Cys modified individual Au@Ag core-shell nanocuboids (CSNCs) | LIC | Extended helical conformation of chemisorbed cysteine molecules | -/- | Recognition |
| |
| NALC-Au NPs | LIC | L-Tyr | -/- | Detection and separation |
| |
| D-/L-Cys-Au NPs | LIC | Racemic propylene oxide (PO) | 0.5 M-/- | Separation |
| |
| Bovine serum albumin enantioselective films coupled with Ag-enhanced Au NPs | LIC | Quantitatively analysis of chiral amino acids | L-Trp: 1.33×10-12-1×10-9 M/5×10-13 M | Detection |
| |
| L-/D-Au gammadion structures | IC | Sensing proteins with β-sheet contents | At pg level/At pg level | Detection |
| |
|
| ||||||
| Uridine 5′-triphosphate (UTP)-capped Ag NP | LIC | Racemic Cys | D-Cys: 0.1-100 μM/100 nM (limit of separation) | Separation and detection |
| |
| L-Arg-Zn Tetraphenylporphyrin-Ag NPs (L-Arg-ZnTPPS-Ag NPs) | LIC | L-His | 5.0×10-6-2.5×10-5 M/- | Recognition |
| |
| DNAzyme-induced asymmetric Ag NP dimers | LIC | Pb2+ | 0.05-10 ng/mL/0.02 ng/mL | Detection |
| |
| L-/D-Au NPs | CAM | Enantiomers of cysteine containing disulfide bond | -/- | Recognition |
| |
| Chiral nanostructured Au films (CNAFs) | CAM | Various enantiomers | -/- | Recognition |
| |
|
| ||||||
| L-Trp-rGO@ Pt NPs/ glassy carbon electrode (L-Trp-rGO@Pt NPs/GCE) GCE | LIC | DOPA enantiomers | 5.0×10-8-5.0×10-3 M/1.7×10-8 M | Detection |
| |
|
| ||||||
| A superstructure of chiral gold nanohybrids and QDs | CAM | H5N1 | 10 pg-10 μg/mL/1 pg/mL | Detection |
| |
| H4N6 | In PBS buffer | In complex 100-0.01 HAU/50 μL/0.0315 HAU/50 μL | ||||
| Infectious | 102-104 EID/50 μL | |||||
| Fowl adenoviruses-9 (FAdVs-9) | -/33.64 PFU/mL | |||||
*CAM represents for Chiral-Assemblies and Morphologies, LIC represents for Ligand Induced Chirality while IC represents for Intrinsic Chirality.
Figure 10The cellular uptake and cytotoxicity. A. Cys-cobalt oxide SPs. B. GSH-Au nanooctopods. Panel A is adapted with permission from 185, copyright 2019 WILEY-VCH. Panel B is adapted with permission from 186, copyright 2021 Chinese Chemical Society.
Figure 11Summary of cyto-toxicity of recent chiral NPs. A. D-Cys-MoO2 NPs. B. L-Cys-MoO2 NPs; C. D-Cys-MoO2.8 NPs; D. L-Cys-MoO2.8 NPs; E. CuxCoyS NPs; F. Cys-CdSe/CdS dot/rod NCs; G. L3.3 and D3.3; H. AuCuAu NRs; I. Cys-Cu2-xS NCs; J. Cys-Cu2-xS NCs; K. Cys-HgS QDs; L. NIBC-HgS QDs. Panel A-D are adapted with permission from 6, copyright 2020 Wiley-VCH. Panel E is adapted with permission from 109, copyright 2020 Wiley-VCH. Panel F is adapted with permission from 85, copyright 2019 the Royal Society of Chemistry. Panel G is adapted with permission from 97, copyright 2020 Springer Nature. Panel H is adapted with permission from 90, copyright 2020 Wiley-VCH. Panel I-J are adapted with permission from 78, copyright 2020 Wiley-VCH. Panel K-L are adapted with permission from 79, copyright 2019 Elsevier.
Cytotoxicity of recent transition metal chiral nanomaterials
| Material | Cell type | LTC | Reference |
|---|---|---|---|
| D-/L-Cys-MoO2.8 | HeLa | 200 µg/mL |
|
| D-/L-Cys-MoO2 | HeLa | 50 µg/mL |
|
| D-/L-Cys-Phe-AuCuAu HNRs | HeLa | 50 µg/mL |
|
| D-/L-Cys-CdSe/ZnS QDs | EAC | 20 µM |
|
| Pen-CuxCoyS NPs | IMR-90 | 60 nM |
|
| D-/L-GSH-Au NPs | SH-SY5Y | 250 nM |
|
| D-/L-NIBC-HgS QDs | INS-1 | 20 mg/mL |
|
| D-/L-Cys-HgS QDs | INS-1 | 10 mg/mL |
|
| D-/L-Cys-CdSe/CdS dot/rod NCs | HeLa | 5 nΜ |
|
| D-/L-Cys-Cu2-xS NCs | HUVECs | 120 µg/mL |
|
| D-/L-Cys-Cu2-xS NCs | 3T3 | 120 µg/mL |
|
| L-Cys-Cu2-xS NCs | HepG2 | 120 µg/mL |
|
| D-Cys-Cu2-xS NCs | HepG2 | 80 µg/mL |
|
| L-Cys-Cu2-xS NCs | HeLa | 120 µg/mL |
|
| D-Cys-Cu2-xS NCs | HeLa | 80 µg/mL |
|
Figure 12Main organ damages evaluation caused by different chiral NPs after intravenous and in situ injection into mice. A. AuCuAu NRs; B. L3.3 and D3.3. Panel A: Adapted with permission from 90, copyright 2020 Wiley-VCH. Panel B: Adapted with permission from 97, copyright 2020 Springer Nature.
Figure 13Biodistribution and clearance of different chiral NPs after intravenous injection into mice. A. GSH@Se NPs; B. SS15; C. AuCuAu NRs; D. AuCuAu NRs; E. GSH@Se NPs. Panel A is adapted with permission from 110, copyright 2019 Wiley-VCH. Panel B is adapted with permission from 89, copyright 2017 Wiley-VCH. Panel C-D are adapted with permission from 90, copyright 2020 Wiley-VCH. Panel E is adapted with permission from 110, copyright 2019 Wiley-VCH.